The Research Stack People Ask About After a Scope, and the Gaps in the Human Data

The story below is a composite of real experiences; details changed.

“Run the Wolverine stack, bro. You’ll be squatting in a month.”

Two weeks after his knee scope, that’s the message waiting in Jordan Price’s gym group chat. Someone adds a third peptide. His sister-in-law suggests collagen.

Jordan is 35 and runs a warehouse crew. He can’t afford a slow recovery. He can’t afford a bad one either.

Everyone in the chat is sure. Nobody in the chat has a study. Here’s what the studies actually say, and where the human data run out.

Why stacks sound convincing

A stack feels thorough. If one thing might help, three things must cover more ground.

That’s not how evidence works. Each compound has its own unknowns. Put them together and you add new ones: how they interact, which one caused a side effect, and whether any of it worked.

What’s actually been studied in people

Sources: FDA briefings on BPC-157 and TB-500; FDA on GHK-Cu; copper-peptide review, Cosmetics, 2018; collagen pilot trial, Nutrients, 2019; ClinicalTrials.gov.

The most-studied item on the list is the supplement, and even that rests on small trials. The three peptides rely mostly on animal and lab work.

For the deep dive on the most popular one, read what the BPC-157 research actually shows.

For how TB-500 and BPC-157 compare in the research, see the side-by-side.

For a short profile of each compound on that list, see the Peptides Made Simple peptide library (written by the team behind After the Scope): BPC-157, TB-500 and GHK-Cu.

The gaps nobody posts about

Three gaps show up again and again.

• No combination studies. We found no published research testing these peptides together in people.
• No surgery trials. We found no published results for any of them after arthroscopic surgery.
• Uneven quality. In July 2026, FDA staff said available paperwork for BPC-157 and TB-500 lacked tests for impurities, clumping and bacterial toxins. They also flagged the risk of immune reactions. (FDA, BPC-157; FDA, TB-500)

An FDA advisory panel voted that month to recommend letting pharmacies compound BPC-157 and TB-500, against staff advice. The vote isn’t binding, and as of mid-September 2026 no final rule had been issued. (Frier Levitt) None of these peptides is an FDA-approved drug.

If your knee is worse than before the scope, the stack isn’t the first question. Start with what can make a knee worse after a meniscus scope.

Bring the chat to the clinic

You don’t have to argue with the group chat. Take the question to the people who have seen your joint from the inside.

For the timeline itself, see when you can return to your kind of work after meniscus surgery.

Before you trust any product’s paperwork, learn how to read a peptide COA.

Muted, not ignored

Jordan mutes the chat. He screenshots the “stack” and brings it to his two-week visit anyway.

His surgeon reads it, shrugs and hands him a printed rehab plan. “This part has studies behind it. Let’s nail it first.”

The stack with the most evidence is still a plan, a therapist and time. Bring your questions. Leave with a plan you can measure.

Your next step: screenshot the five questions above and ask the first one at your next post-op visit.

---

Jordan is a composite, drawn from the kinds of stories people describe after arthroscopic surgery. The details are illustrative. This article is education, not medical advice. It does not cover dosing or use.